Archives

Results of a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

Kathy Miller, Sara M. Tolaney, Leisha Emens, Sung-Bae Kim, Erika Hamilton, Cristina Saura, Lucia Sanz, Valentina Boni, Filipa Lynce, Juan M. Cejalvo, Jennifer A. Crozier, Shirley Wang, Shannon Tsai, Hojjat Bazzazi, Hirdesh Uppal, Alison Hannah, Sara Hurvitz. Poster presented at the San Antonio Breast Cancer Symposium®, December 6-10, 2022.

Learn More

Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of the Probody® Therapeutic (Pb-Tx) Praluzatamab Ravtansine (CX-2009) in Metastatic HR-Positive/HER2-Negative Breast Cancer (mHR+/HER2− BC) and of CX-2009 as Monotherapy and in Combination Therapy With Pacmilimab (CX-072) in Metastatic Triple-Negative Breast Cancer (TNBC)

Kathy D. Miller, Leisha A. Emens, Sara M. Tolaney, Sara A. Hurvitz, Erika Hamilton, Virginia Paton, Alison Hannah, Valentina Boni. Poster presented at the San Antonio Breast Cancer Symposium®, December 8-11, 2020.

Learn More

Intratumoral Activation and Phase 1/2 Clinical Activity of Praluzatamab Ravtansine (CX-2009), a Probody® Drug Conjugate (PDC) Targeting CD166

Liu J, Zein IA, Dang T, Lyman SK, Wang S, Spira A, Uboha N, LoRusso P, Fidler MJ, Meric-Bernstam F, Arkenau T, Nagasaka M, Desnoyers LR, Kavanaugh WM, Paton VE, Hannah AL, Boni V. Poster presented at the San Antonio Breast Cancer Symposium®, December 8-11, 2020.

Learn More

CX-2009, a CD166-Directed PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study in Patients With Advanced Cancer Including Breast Cancer

Valentina Boni, Howard Burris, Joyce Liu, Alexander Spira, Hendrik-Tobias Arkenau, Mary Josephine Fidler, Lee Rosen, Randy F. Sweis, Nataliya Uboha, Rachel E. Sanborn, Bert O’Neil, James Harding, Patricia LoRusso, Amy Weise, Javier Garcia-Corbacho, Ivan Victoria, Mark Stroh, Rachel Li, Alison Hannah, Ginny Paton, Funda Meric-Bernstam. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Preliminary Clinical Pharmacokinetics and Dose-Response to Support a Phase 2 Dose Selection for CX-2009: A Masked PROBODY Drug Conjugate to CD166

Mark Stroh, Rachel Li, Hong Lu, Russ Wada, Jennifer Richardson, Amy Peterson. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Preliminary Results of PROCLAIM-CX-2009, a First-in-Human, Dose-Finding Study of the Probody™ Drug Conjugate CX-2009 in Patients With Advanced Solid Tumors

Funda Meric-Bernstam, Valentia Boni, Alexander Spira, Rachel E. Sanborn, Hendrik-Tobias Arkenau, Randy F. Sweis, Howard Burris, Rui Li, Pratigya Gautam, Sreeni Yalamanchili, Matthias Will, Joyce F. Liu, James J. Harding. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia.

Learn More

A Probody™ Drug Conjugate Targeting CD166 (ALCAM) Enhances Preclinical Antitumor Activity of a Probody Therapeutic Targeting PD-1

Erwan Le Scolan, Tiffany Tse, Michael Krimm, Will Garner, Hikmat Assi, Jennifer Razo, Laurie Wong, Kenneth R. Wong, Victoria Singson, Jennifer Leong, Linnea Diep, Jennifer H. Richardson, Siew Schleyer, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia

Learn More

CD166-DM4 Probody™ Drug Conjugate (CX-2009) Treatment of 198 Patient -derived Xenograft Models (PDX) in a Mouse Clinical Trial Format

Bob Y. Liu, Joel Shen, Matthias Will, Sreeni Yalamanchili, Judi Ford-Gordon, Mark Stroh, Jennifer Richardson, Annie Yang-Weaver, Luc R. Desnoyers, Marcia Belvin, W. Michael Kavanaugh, Siew Schleyer. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia.

Learn More

Development of a Probody™ Drug Conjugate (PDC) Targeting CD166 for the Treatment of Multiple Cancers

Annie Yang Weaver, Shweta Singh, Amy DuPage, Jason Sagert, Jeanne Flandez, Elizabeth Menendez, Judi Ford, Michael Krimm, Stephen Moore, Margaret Nguyen, Andrew Jang, Eric Brecht, Yuanhui Huang, Linnea Diep, Nicole Lapuyade, Tereza Sputova, James West, Olga Vasiljeva, Shouchun Liu, Jennifer Richardson, W. Michael Kavanaugh, Jonathan A. Terrett, Luc R. Desnoyers. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015, November 5-9, Boston, Massachusetts.

Learn More

PROCLAIM-CX-2009: A First-in-Human Trial to Evaluate CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors

Javier Garcia-Corbacho, Alexander Spira, Valentina Boni, Jaime Feliu, Mark Middleton, Howard Burris, Annie Yang Weaver, Matthias Will, James Harding, Funda Meric-Bernstam, Volker Heinemann. Poster presented at ESMO 2017, September 8-12, Madrid, Spain.

Learn More